DynamX Bioadaptor Shows 88% Reduction in Cardiovascular Death Compared to Drug-Eluting Stents in Four-Year Trial
核心洞察
Elixir Medical (搜索)'s DynamX Bioadaptor demonstrated significantly lower target lesion failure rates (2.8% versus 7.8%, p=0.020) compared to Resolute Onyx drug-eluting stents in the 445-patient BIOADAPTOR randomized controlled trial.
The bioadaptor achieved an 88% reduction in cardiovascular death (0.5% versus 3.7%, p=0.020) with no new events in the bioadaptor arm between three and four years.
Unlike traditional drug-eluting stents that permanently cage arteries, the DynamX bioadaptor unlocks after six months to restore vessel pulsatility and compliance while maintaining arterial support.
Elixir Medical (搜索) announced groundbreaking four-year results from its BIOADAPTOR randomized controlled trial at EuroPCR 2026, demonstrating that the company's DynamX Coronary Bioadaptor System achieved an 88% reduction in cardiovascular death compared to standard drug-eluting stents. The 445-patient international trial showed significantly lower target lesion failure rates with the bioadaptor (2.8% versus 7.8%, p=0.020) compared to Medtronic's Resolute Onyx Drug-Eluting Stent.
Revolutionary Approach to Arterial Restoration
The DynamX bioadaptor represents a fundamental departure from traditional stent technology. While drug-eluting stents permanently cage arteries with rigid scaffolding, the bioadaptor is designed to restore natural vessel function after an initial healing period.
"Interventional cardiologists typically use a drug-eluting stent (DES) during percutaneous coronary intervention (PCI) to open the heart blockage and keep the artery open. These interlocked mesh-like tubes, however, permanently cage the artery, limiting its function and contributing to an annual 2-3% increase in adverse clinical events over time," explained Professor Stefan Verheye, M.D., Ph.D., interventional cardiologist at ZNA Cardiovascular Center in Antwerp, Belgium and leading DynamX investigator.
The bioadaptor initially functions like a traditional stent, establishing luminal diameter to improve blood flow. However, after six months, a bioresorbable polymer coating dissolves, allowing the device's helical strands to unlock and separate. This transformation enables the treated vessel to recover pulsatility and compliance while maintaining essential radial support.
Sustained Clinical Benefits Over Time
The four-year data revealed a striking pattern of sustained clinical benefit. Most notably, no new target lesion failure or cardiovascular death events occurred in the bioadaptor arm between years three and four, demonstrating a plateauing of adverse events rather than the continued annual increase typically seen with drug-eluting stents.
The 66% reduction in target lesion failure was driven by improvements across all components of the device-related combined endpoint, including:
- 88% lower cardiovascular death (0.5% versus 3.7%, p=0.020)
- Numerically lower target vessel myocardial infarction (0.9% versus 1.8%)
- Numerically lower clinically driven target lesion revascularization (1.4% versus 2.8%)
Enhanced Performance in Critical Vessel
The benefits were particularly pronounced in the left anterior descending (LAD) artery, responsible for approximately 50% of heart blood supply. In this hemodynamically critical vessel, target lesion failure rates were dramatically lower with DynamX compared to drug-eluting stents (2.7% versus 10.6%, p=0.021).
"The significant finding in reducing cardiovascular mortality marks a major achievement in how we treat cardiovascular disease and improve patient outcomes," remarked Shigeru Saito, M.D., trial principal investigator and director of the Division of Cardiology and Catheterization Laboratory at Shonan Kamakura General Hospital in Kamakura, Japan.
Comprehensive Clinical Evidence Program
The BIOADAPTOR RCT is part of Elixir Medical (搜索)'s robust clinical evidence program consisting of nine company-sponsored and investigator-initiated studies involving over 9,000 patients. The international, single-blind, randomized controlled trial compared a sirolimus-eluting bioadaptor with a contemporary zotarolimus-eluting stent across 34 centers in Japan, Europe, and New Zealand.
Results from the larger 2,400-patient INIFINITY-SWEDEHEART RCT have shown consistent findings, with significantly lower, plateauing clinical events with the DynamX bioadaptor compared to drug-eluting stent treatment across multiple randomized clinical trials.
"The four-year BIOADAPTOR-RCT data presented today, and the results from the 2,400 patient INIFINITY-SWEDEHEART RCT have shown consistently across multiple randomized clinical trials significantly lower, plateauing clinical events with DynamX bioadaptor compared to DES treatment, demonstrating the clear benefit of restoring a key function of arteries, hemodynamic modulation, with this breakthrough technology," said Motasim Sirhan, CEO of Elixir Medical (搜索).
Regulatory Status and Market Position
The DynamX Sirolimus Eluting Coronary Bioadaptor System is CE-marked for use in Europe, while remaining investigational in the United States. The device has received FDA Breakthrough Device Designation, designed to expedite review of technologies that could provide more effective treatment for life-threatening diseases.
Elixir Medical (搜索), a privately held company based in Milpitas, California, was named to Fast Company's prestigious list of the World's Most Innovative Companies of 2025. The company's transformative technology addresses known limitations of both drug-eluting stents and bioresorbable scaffolds, with clinical event rates showing a plateau from six months through four-year follow-up.